To enhance the practical utility and applicability of the TCGA classification, more cost-effective alternatives to molecular prognostic markers (specifically, the immunohistochemical evaluation of MMR proteins and p53) were developed, and the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) was established by grouping four groups that mirror the TCGA prognostic categories: POLE-mutated (POLEmut), MMR-deficient (MMRd), p53-abnormal (p53abn), and no specific molecular profile (NSMP) [57]. The gene discussed is MRC1; the disease is endometrial cancer.